What type of study is this?

August 20, 2025The OncologistOpen Access

Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials

View Full Paper

Ask AI

Bookmark

Invasive disease-free survival showed a strong correlation with overall survival, indicating its effectiveness as a surrogate endpoint.
At five years, the hazard ratio for invasive disease-free survival exceeded 0.7, demonstrating strong predictive validity for overall survival.
Surrogacy analyses across multiple randomized trials highlighted the importance of breast cancer subtype in selecting endpoints.
On average, intermediate and high-risk tumors displayed the highest correlations, reinforcing the relevance of tumor characteristics.

No takes yet. Share an insight, caveat, or question.

Analysis reveals adjuvant chemotherapy endpoints effectively predict overall survival in breast cancer patients, suggesting tailored approaches.

Blasco et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals adjuvant chemotherapy endpoints effectively predict overall survival in breast cancer patients, suggesting tailored approaches.